《業績快報》藥明康德(02359.HK)料上半年淨利潤按年增約62.5%至17.2億人幣
藥明康德(02359.HK)公布,公司今年上半年整體營業收入預計按年增長約22.68%至72.3億元人民幣(下同),淨利潤預計按年增長約62.49%至17.2億元,基本每股收益預計按年增長約63.04%。
公司指,逐步從新型冠狀病毒肺炎疫情中恢復過來,並在第二季度實現強勁增長。與去年第二季度相比,公司營業收入預計按年增長約29.41%至40.4億元,淨利潤預計按年增長約111.46%至14.1億元,基本每股收益預計按年增長約110.34%。
公司提到,營業總收入在公司美國區實驗室服務的收入和利潤因為今年第二季美國新冠疫情加重受到較大負面影響的情況下,公司中國區實驗室服務及CDMO(合同開發生產服務)服務分部已全面運營,且海外客戶的需求增加。得益於強勁需求、產能利用及經營效率的提升,集團於第二季實現營業收入強勁增長。同時,集團的臨床CRO(合同研究服務)及SMO(現場管理服務)服務也處於逐步恢復中。
非經常性項目方面,今年上半年,公司的非經常性項目金額較去年同期有所增長,主要是由於若干投資組合公司的市場價值上漲,使本公司投資組合產生公允價值收益約10.3億元,而去年同期的公允價值虧損為1,825萬元。其中,公司於報告期間變更對一間投資組合公司的會計核算方式,從而確認投資收益3.51億元,惟部分被公司於去年發行的可轉換債券的轉換權非現金價值升值導致公允價值虧損4.87億元所抵銷。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.